Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells

Anti-Cancer Agents in Medicinal Chemistry, 10(7): 543-555.

Author(s): Chunhui Di, Austin K. Mattox, Stephen Harward and Cory Adamson.

Affiliation: Preston Robert Tisch Brain Tumor Center, Departments of Surgery (Neurosurgery) and Neurobiology, Duke University; Neurosurgery Section, Durham VA Medical Center, DUMC Box 2624, Durham, NC 27710, USA.


Glioblastoma multiforme (GBM) is one of the most common and most aggressive types of primary brain tumors in humans. Even with aggressive surgical resections using state of the art preoperative and intraoperative neuroimaging, along with the most recent techniques in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal. Survival after diagnosis is about 12-14 months. The tumor cells which already have migrated into normal brain tissue beyond the surgical resection margin account for the inability to effectively treat this tumor. Understanding how to control the migration of GBM cells is paramount to future therapies. In this review, we will focus on the emerging targets and agents which are being exploited to inhibit the migration of glioma cells in GBM.


Glioblastoma, tumor cell migration, AJAP, chemotherapy, astrocytoma, parenchyma, fibronectin, methylisoxazole, GDNF, amphiregulin, epigen, phospho-tyrosine, transcription factors, heterodimers, predominant, GDNF family, vitronectin, laminin, ERK, sphingosine-1-phosphate, FLIPS protein, Granulocyte-colony, IGFBP2 promotes, actinin, oligodendroglioma tumors, MAPK, bevacizumab, crossroads.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 7
First Page: 543
Last Page: 555
Page Count: 13
DOI: 10.2174/187152010793498618
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science